ATRA
Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.96
−2.40%Year over year
Reported trailing growth
- Revenue
- -96.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +65.8%
- Operating cash flow
- +65.7%
Forward estimates
Based on analyst estimates
- Revenue
- +444.9%
- EBITDA
- +230.9%
- EPS
- +166.0%
Three-year CAGR
- Revenue
- +23.9%
- EBITDA
- +151.0%
- EBIT
- +143.0%
- Net income
- +138.3%
- EPS
- +122.9%
- Free cash flow
- +26.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026